27753022|t|Implementing Non-Invasive Prenatal Diagnosis (NIPD) in a National Health Service Laboratory; From Dominant to Recessive Disorders
27753022|a|Our UK National Health Service regional genetics laboratory offers NIPD for autosomal dominant and de novo conditions (achondroplasia, thanataphoric dysplasia, Apert syndrome), paternal mutation exclusion for cystic fibrosis and a range of bespoke tests. NIPD avoids the risks associated with invasive testing, making prenatal diagnosis more accessible to families at high genetic risk. However, the challenge remains in offering definitive diagnosis for autosomal recessive diseases, which is complicated by the predominance of the maternal mutant allele in the cell-free DNA sample and thus requires a variety of different approaches. Validation and diagnostic implementation for NIPD of congenital adrenal hyperplasia (CAH) is further complicated by presence of a pseudogene that requires a different approach. We have used an assay targeting approximately 6700 heterozygous SNPs around the CAH gene (CYP21A2) to construct the high-risk parental haplotypes and tested this approach in five cases, showing that inheritance of the parental alleles can be correctly identified using NIPD. We are evaluating various measures of the fetal fraction to help determine inheritance of parental mutations. We are currently exploring the utility of an NIPD multi-disorder panel for autosomal recessive disease, to make testing more widely applicable to families with a variety of serious genetic conditions.
27753022	0	12	Implementing	T052	C1708476
27753022	13	25	Non-Invasive	T169	C0205303
27753022	26	44	Prenatal Diagnosis	T060	C0033053
27753022	46	50	NIPD	T060	C0033053
27753022	57	91	National Health Service Laboratory	T073,T093	C0022877
27753022	98	106	Dominant	T169	C1527180
27753022	110	119	Recessive	T045	C0678943
27753022	120	129	Disorders	T047	C0012634
27753022	134	189	UK National Health Service regional genetics laboratory	T073,T093	C0022877
27753022	197	201	NIPD	T060	C0033053
27753022	206	224	autosomal dominant	T045	C0443147
27753022	229	236	de novo	T078	C1515568
27753022	237	247	conditions	T080	C0348080
27753022	249	263	achondroplasia	T019	C0001080
27753022	265	288	thanataphoric dysplasia	T019	C0039743
27753022	290	304	Apert syndrome	T019	C0001193
27753022	307	315	paternal	T080	C0337493
27753022	316	324	mutation	T045	C0026882
27753022	325	334	exclusion	T169	C0680251
27753022	339	354	cystic fibrosis	T047	C0010674
27753022	370	383	bespoke tests	T060	C0683443
27753022	385	389	NIPD	T060	C0033053
27753022	401	406	risks	T033	C0035648
27753022	407	422	associated with	T080	C0332281
27753022	423	439	invasive testing	T060	C0430022
27753022	448	466	prenatal diagnosis	T060	C0033053
27753022	467	471	more	T081	C0205172
27753022	486	494	families	T099	C0015576
27753022	498	502	high	T080	C0205250
27753022	503	515	genetic risk	T081	C1517512
27753022	560	570	definitive	T079	C0443196
27753022	571	580	diagnosis	T033	C0011900
27753022	585	613	autosomal recessive diseases	T047	C0265388
27753022	624	635	complicated	T169	C0231242
27753022	643	655	predominance	T080	C0332251
27753022	663	671	maternal	T099	C0026591
27753022	672	678	mutant	T049	C0596988
27753022	679	685	allele	T028	C0002085
27753022	693	706	cell-free DNA	T114	C4289789
27753022	707	713	sample	T077	C2347026
27753022	734	741	variety	T077	C2346866
27753022	745	754	different	T080	C1705242
27753022	755	765	approaches	T082	C0449445
27753022	767	777	Validation	T062	C1519941
27753022	782	792	diagnostic	T169	C0348026
27753022	793	807	implementation	T052	C1708476
27753022	812	816	NIPD	T060	C0033053
27753022	820	850	congenital adrenal hyperplasia	T047	C0001627
27753022	852	855	CAH	T047	C0001627
27753022	868	879	complicated	T169	C0231242
27753022	883	891	presence	T033	C0150312
27753022	897	907	pseudogene	T028	C0033799
27753022	924	933	different	T080	C1705242
27753022	934	942	approach	T082	C0449445
27753022	960	965	assay	T059	C0005507
27753022	966	975	targeting	T169	C1521840
27753022	976	989	approximately	T080	C0332232
27753022	995	1007	heterozygous	T032	C0019425
27753022	1008	1012	SNPs	T086	C0752046
27753022	1024	1032	CAH gene	T028	C1413861
27753022	1034	1041	CYP21A2	T028	C1413861
27753022	1060	1069	high-risk	T033	C0332167
27753022	1070	1078	parental	T099	C0030551
27753022	1079	1089	haplotypes	T032	C0018591
27753022	1106	1114	approach	T082	C0449445
27753022	1143	1154	inheritance	T081	C0242538
27753022	1162	1170	parental	T099	C0030551
27753022	1171	1178	alleles	T028	C0002085
27753022	1196	1206	identified	T080	C0205396
27753022	1213	1217	NIPD	T060	C0033053
27753022	1245	1253	measures	T081	C0079809
27753022	1261	1266	fetal	T018	C0015965
27753022	1294	1305	inheritance	T081	C0242538
27753022	1309	1317	parental	T099	C0030551
27753022	1318	1327	mutations	T045	C0026882
27753022	1360	1367	utility	T080	C3827682
27753022	1374	1378	NIPD	T060	C0033053
27753022	1379	1399	multi-disorder panel	T059	C0022885
27753022	1404	1431	autosomal recessive disease	T047	C0265388
27753022	1441	1448	testing	T169	C0039593
27753022	1461	1471	applicable	T080	C1706839
27753022	1475	1483	families	T099	C0015576
27753022	1502	1509	serious	T080	C0205404
27753022	1510	1528	genetic conditions	T047	C0019247